Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Chest PNF on Pulmonary Function in Parkinson Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03977740
Recruitment Status : Recruiting
First Posted : June 6, 2019
Last Update Posted : June 6, 2019
Sponsor:
Information provided by (Responsible Party):
Subhasish Chatterjee, Maharishi Markendeswar University (Deemed to be University)

Brief Summary:

Background: Parkinson disease (PD) is a progressive neurodegenerative disorder and characterized by tremor, rigidity and bradykinesia. Almost 84% of PD patient develops respiratory abnormalities and pointed as the most common cause of death. Airway obstruction, trunk muscle rigidity is the common cause of respiratory abnormalities.

Purpose: The main purpose of the study will evaluate the efficacy of chest PNF on pulmonary function and chest wall mobility in PD.

Methods: 20 participants will be recruited for study purpose and divide into two groups. Group= A will be the control group and participants will receive conventional treatment which includes deep breathing exercise and segmental breathing exercise, incentive spirometry etc for one week. Group= B participants will receive chest PNF exercise along with conventional treatment for a week. Pretreatment and post-treatment data will be recorded by the help of PFT (FVC, FEV1 & FEV1/FVC) and chest wall expansion at axillary and xiphisternal level for data analysis. Data analysis will be done by paired t-test for within group and independent t-test will be used for the between-group variable. The level of significance will be set at 0.05.


Condition or disease Intervention/treatment Phase
Parkinson Disease Other: chest PNF Other: Conventional Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy of Chest PNF on Pulmonary Function in Patients With Parkinson's Diseases
Actual Study Start Date : January 1, 2018
Estimated Primary Completion Date : June 10, 2019
Estimated Study Completion Date : June 10, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: chest PNF

participants received conventional chest physiotherapy along with chest PNF technique 5 days for 1 week.

Chest PNF technique includes oblique downward pressure at the sternum, diagonal pressure at lower rib cage at the supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on the elbow.

Other: chest PNF
Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.

Active Comparator: Conventional
participants received conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
Other: Conventional
conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer




Primary Outcome Measures :
  1. Pulmonary Function Test (PFT) [ Time Frame: changes bwtween baseline to 1 week ]
    Pulmonary functions parameters FVC in litre, FEV1 in litre and ratio between FVC/FEV1 will be recorded with PFT


Secondary Outcome Measures :
  1. chest wall expansion by inch tape [ Time Frame: changes bwtween baseline to 1 week ]
    chest wall expansion will be measured at axillary and xiphisternal level



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Grade 3 to grade 5 Parkinson patients according to Hoehn Yahar scale
  2. MMSE score >23.
  3. Age 50-70 yrs.
  4. Both Male and Female.

Exclusion Criteria:

  1. Previous history of cardiac and pulmonary surgery.
  2. History of flail chest.
  3. Individual affected by neurological disorder other than PD.
  4. Uncooperative patients.
  5. Individual with the psychosomatic disorder.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03977740


Contacts
Layout table for location contacts
Contact: Mousumi Saha, MPT 9366787310 msaha0029@gmail.com
Contact: Nidhi Sharma 7906134419

Locations
Layout table for location information
India
MMIPR Recruiting
Ambāla, Haryana, India, 133207
Contact: Mousumi Saha, MPT       msaha0029@gmail.com   
Sponsors and Collaborators
Subhasish Chatterjee
Layout table for additonal information
Responsible Party: Subhasish Chatterjee, clinical professor, Maharishi Markendeswar University (Deemed to be University)
ClinicalTrials.gov Identifier: NCT03977740    
Other Study ID Numbers: IEC-1111
First Posted: June 6, 2019    Key Record Dates
Last Update Posted: June 6, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases